CERCA
MCID: CRV035
MIFTS: 76

Cervical Cancer (CERCA)

Categories: Cancer diseases, Genetic diseases, Reproductive diseases

Aliases & Classifications for Cervical Cancer

MalaCards integrated aliases for Cervical Cancer:

Name: Cervical Cancer 58 39 12 77 76 38 56 44 3 15 64 74
Uterine Cervical Neoplasms 6 45
Uterine Cervical Neoplasm 12 74
Cervical Cancer, Somatic 58 13
Cervix Cancer 12 76
Neoplasm of Uterine Cervix 12
Tumor of the Cervix Uteri 12
Cancer, Cervical, Somatic 41
Malignant Tumor of Cervix 74
Uterine Cervical Cancer 76
Cervix Uteri Cancer 12
Neoplasms Cervical 56
Cervical Neoplasm 12
Cervix Carcinoma 74
Cerca 76

Characteristics:

HPO:

33
cervical cancer:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:4362
OMIM 58 603956
KEGG 38 H00030
ICD9CM 36 180 180.9
MeSH 45 D002583
NCIt 51 C2940 C9311
SNOMED-CT 69 93752005
ICD10 34 C53 C53.9
SNOMED-CT via HPO 70 108369006 124975008 363346000

Summaries for Cervical Cancer

MedlinePlus : 44 The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection. Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. Vaccines can protect against several types of HPV, including some that can cause cancer. NIH: National Cancer Institute

MalaCards based summary : Cervical Cancer, also known as uterine cervical neoplasms, is related to cervix carcinoma and cervix disease, and has symptoms including pelvic pain An important gene associated with Cervical Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Human papillomavirus infection and Viral carcinogenesis. The drugs Cervarix and Gardasil have been mentioned in the context of this disorder. Affiliated tissues include cervix, testes and lymph node, and related phenotypes are neoplasm and abnormality of the cervical spine

Disease Ontology : 12 A female reproductive organ cancer that is located in the cervix.

CDC : 3 Early on, cervical cancer may not cause signs and symptoms. Advanced cervical cancer may cause bleeding or discharge from the vagina that is not normal for you, such as bleeding after sex. If you have any of these signs, see your doctor. They may be caused by something other than cancer, but the only way to know is to see your doctor.

UniProtKB/Swiss-Prot : 76 Cervical cancer: A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.

PubMed Health : 64 About cervical cancer: Cervical cancer is the term used to describe tumors that can grow at the lower end of the womb. These tumors usually develop from abnormal cell changes at the entrance to the womb from the vagina (the opening of the cervix). Abnormal cell changes can be detected through screening and then removed. A vaccine against viruses that cause cancer (HPV vaccine) can reduce the risk of cervical cancer.The cervix (neck of the womb) is a strong, muscular tube-like structure. The very bottom end of the cervix sticks out into the vagina a little, at the opening of the cervix. The inside of the cervix is lined with a mucous membrane. Glands in the mucous membrane produce a thick liquid (cervical mucus) that acts as a barrier, preventing germs from entering the womb from the vagina.

Wikipedia : 77 Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

Description from OMIM: 603956

Related Diseases for Cervical Cancer

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 452)
# Related Disease Score Top Affiliating Genes
1 cervix carcinoma 33.1 FGFR3 STAT3 TP53
2 cervix disease 32.7 AKT1 CCND1 CTNNB1 TP53
3 papilloma 32.1 CCND1 FGFR3 PTEN TP53
4 squamous cell carcinoma 31.9 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 HOTAIR
5 adenocarcinoma 31.4 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
6 breast cancer 31.4 AKT1 CCND1 CTNNB1 ERBB2 GNAS HOTAIR
7 endometrial cancer 31.3 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR HRAS
8 ovarian cancer 31.2 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR MIR21
9 sarcoma 31.2 CTNNB1 HOTAIR HRAS MTOR PIK3CA TP53
10 lung cancer 31.0 AKT1 CCND1 ERBB2 FGFR3 HOTAIR HRAS
11 kaposi sarcoma 30.9 AKT1 MTOR STAT3 TP53
12 prostate cancer 30.9 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR HRAS
13 gastric cancer 30.8 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR MIR21
14 colorectal cancer 30.8 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
15 ovarian cancer 1 30.7 AKT1 ERBB2 PIK3CA TP53
16 hepatocellular carcinoma 30.7 AKT1 CCEPR CCND1 CTNNB1 GNAS HOTAIR
17 lung cancer susceptibility 3 30.7 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
18 small cell cancer of the lung 30.7 AKT1 HOTAIR MIR21 PIK3CA PTEN TP53
19 colorectal adenoma 30.6 CTNNB1 HRAS TP53
20 adenoma 30.6 CCND1 CTNNB1 GNAS SMAD4 TP53
21 esophageal cancer 30.6 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR HRAS
22 carcinosarcoma 30.6 CTNNB1 ERBB2 HRAS PIK3CA PTEN TP53
23 uterine carcinosarcoma 30.6 CTNNB1 ERBB2 HRAS PIK3CA PTEN TP53
24 tongue squamous cell carcinoma 30.5 AKT1 CTNNB1 MIR21 TP53
25 peutz-jeghers syndrome 30.5 CTNNB1 PTEN SMAD4 TP53
26 penile cancer 30.5 CCND1 PIK3CA TP53
27 bladder cancer 30.5 CCEPR CCND1 ERBB2 FGFR3 HOTAIR HRAS
28 osteogenic sarcoma 30.5 AKT1 HOTAIR PVT1 TP53
29 pancreas adenocarcinoma 30.5 AKT1 CCND1 CTNNB1 ERBB2 GNAS HRAS
30 oral cancer 30.4 CCND1 MIR21 TP53
31 primitive neuroectodermal tumor of the cervix uteri 12.6
32 malignant germ cell tumor of the cervix uteri 12.5
33 cervical intraepithelial neoplasia 11.5
34 carcinosarcoma of the cervix uteri 11.4
35 radiation proctitis 11.3
36 cervical carcinosarcoma 11.0
37 cervix melanoma 11.0
38 cervix endometrial stromal tumor 11.0
39 diethylstilbestrol syndrome 11.0
40 glioblastoma multiforme 10.9 AKT1 CCND1 ERBB2 MIR21 MTOR PIK3CA
41 medulloblastoma 10.9 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR PIK3CA
42 glioblastoma 10.8 AKT1 CCND1 ERBB2 HOTAIR HRAS MIR21
43 uterine anomalies 10.8 AKT1 CCND1 CTNNB1 ERBB2 PIK3CA PTEN
44 cholangiocarcinoma 10.8 AKT1 CCND1 CTNNB1 ERBB2 MIR21 MTOR
45 estrogen-receptor positive breast cancer 10.8 AKT1 CCND1 ERBB2 MTOR PIK3CA TP53
46 respiratory system cancer 10.8 AKT1 CCND1 CTNNB1 ERBB2 HRAS PIK3CA
47 bladder disease 10.8 AKT1 CCND1 ERBB2 FGFR3 TP53
48 glioma 10.8 CCND1 ERBB2 HOTAIR MIR21 PIK3CA PTEN
49 adenoid cystic carcinoma 10.8 AKT1 CCND1 CTNNB1 ERBB2 HRAS PIK3CA
50 adamantinoma of long bones 10.8 CCND1 CTNNB1 ERBB2 HOTAIR PIK3CA PTEN

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hydronephrosis Intestinal Obstruction
Vaginal Cancer

Graphical network of the top 20 diseases related to Cervical Cancer:



Diseases related to Cervical Cancer

Symptoms & Phenotypes for Cervical Cancer

Human phenotypes related to Cervical Cancer:

33
# Description HPO Frequency HPO Source Accession
1 neoplasm 33 HP:0002664
2 abnormality of the cervical spine 33 HP:0003319

Clinical features from OMIM:

603956

UMLS symptoms related to Cervical Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Cervical Cancer according to GeneCards Suite gene sharing:

27 (show top 50) (show all 57)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.56 MTOR
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.56 SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.56 MTOR SMAD4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.56 PIK3CA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.56 CCND1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.56 PTEN
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.56 PTEN CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.56 PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.56 AKT1 MTOR PIK3CA PTEN CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.56 CCND1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.56 PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.56 PTEN
13 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.56 AKT1 PIK3CA CCND1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.56 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.56 SMAD4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.56 CCND1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.56 SMAD4 CCND1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.56 CCND1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.56 PTEN
20 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.56 SMAD4 CCND1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.56 CCND1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.56 AKT1 MTOR PIK3CA PTEN SMAD4
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.56 SMAD4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.56 SMAD4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.56 PIK3CA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.56 AKT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.56 SMAD4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.56 PTEN
29 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.56 AKT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.56 MTOR SMAD4
31 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.56 SMAD4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.56 AKT1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.56 SMAD4
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.56 AKT1 MTOR
35 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.56 PTEN
36 Decreased viability GR00055-A-2 10.35 HRAS MTOR PIK3CA
37 Decreased viability GR00221-A-1 10.35 AKT1 FGFR3 HRAS MTOR PIK3CA
38 Decreased viability GR00221-A-2 10.35 AKT1 FGFR3 HRAS PIK3CA
39 Decreased viability GR00221-A-3 10.35 AKT1 FGFR3 HRAS
40 Decreased viability GR00221-A-4 10.35 AKT1 MTOR PIK3CA
41 Decreased viability GR00342-S-1 10.35 MTOR
42 Decreased viability GR00342-S-2 10.35 MTOR
43 Decreased viability GR00402-S-2 10.35 AKT1 FGFR3 HRAS MTOR PIK3CA
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.17 FGFR3
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.17 ERBB2
46 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.17 MTOR
47 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.17 AKT1
48 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.17 PIK3CA
49 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.17 MTOR PIK3CA
50 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 10.17 FGFR3

MGI Mouse Phenotypes related to Cervical Cancer:

47 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.46 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
2 cardiovascular system MP:0005385 10.42 AKT1 CCND1 CTNNB1 ERBB2 GNAS HRAS
3 cellular MP:0005384 10.42 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
4 growth/size/body region MP:0005378 10.41 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
5 homeostasis/metabolism MP:0005376 10.39 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
6 endocrine/exocrine gland MP:0005379 10.35 AKT1 CCND1 CTNNB1 ERBB2 GNAS HRAS
7 integument MP:0010771 10.34 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
8 mortality/aging MP:0010768 10.32 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
9 immune system MP:0005387 10.31 AKT1 CCND1 CTNNB1 FGFR3 GNAS MTOR
10 craniofacial MP:0005382 10.3 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
11 hematopoietic system MP:0005397 10.3 AKT1 CCND1 CTNNB1 FGFR3 GNAS MTOR
12 digestive/alimentary MP:0005381 10.29 CCND1 CTNNB1 ERBB2 FGFR3 HRAS NFE2L2
13 embryo MP:0005380 10.28 AKT1 CTNNB1 ERBB2 MTOR NFE2L2 PIK3CA
14 neoplasm MP:0002006 10.25 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
15 nervous system MP:0003631 10.25 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
16 adipose tissue MP:0005375 10.22 AKT1 GNAS MTOR NFE2L2 PIK3CA PTEN
17 muscle MP:0005369 10.16 AKT1 CTNNB1 ERBB2 GNAS MTOR PIK3CA
18 normal MP:0002873 10.13 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
19 liver/biliary system MP:0005370 10.1 AKT1 CTNNB1 GNAS NFE2L2 PTEN SMAD4
20 limbs/digits/tail MP:0005371 10.05 CTNNB1 ERBB2 FGFR3 GNAS PTEN SMAD4
21 renal/urinary system MP:0005367 9.96 CTNNB1 FGFR3 GNAS HRAS MTOR NFE2L2
22 no phenotypic analysis MP:0003012 9.91 CTNNB1 FGFR3 GNAS HRAS MTOR PIK3CA
23 reproductive system MP:0005389 9.85 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 PIK3CA
24 respiratory system MP:0005388 9.73 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
25 skeleton MP:0005390 9.47 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS

Drugs & Therapeutics for Cervical Cancer

PubMedHealth treatment related to Cervical Cancer: 64

The most appropriate type of treatment will mainly depend on the size of the tumor and whether the cancer has spread. If the tumor is discovered at a very early stage, a small surgical procedure (conization) might be enough. If the tumor has already spread to the surrounding tissue, doctors usually recommend having surgery to remove the entire womb (a hysterectomy). The lymph nodes are removed in a wide area around the womb too. Radiotherapy might also be considered. Radiotherapy is still an option even if the tumor can no longer be removed through surgery. In some patients it can be combined with chemotherapy.

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Cervarix 19 50 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
2
Gardasil 19 50 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 505)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
2
Bethanechol Approved Phase 4 674-38-4 2370
3
Peppermint Approved Phase 4
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
6
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
7
Meperidine Approved Phase 4 57-42-1 4058
8
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
9
Iron Approved, Experimental Phase 4,Phase 1,Phase 2 7439-89-6, 15438-31-0 27284 23925
10
Ferrous fumarate Approved Phase 4 141-01-5
11
Polihexanide Approved, Investigational Phase 4 28757-47-3
12
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
13
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
14
Nicotine Approved Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 54-11-5 89594 942
15
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
16
Tenofovir Approved, Experimental, Investigational Phase 4 147127-20-6 464205
17
Nevirapine Approved Phase 4 129618-40-2 4463
18
Vitamin C Approved, Nutraceutical Phase 4,Phase 2 50-81-7 54670067 5785
19 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
20 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Monophosphoryl lipid A Phase 4
22 Cholinergic Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Muscarinic Agonists Phase 4
27 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Epoetin alfa Phase 4,Phase 3 113427-24-0
31 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
32 Fluorodeoxyglucose F18 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Narcotics Phase 4,Phase 3,Not Applicable,Early Phase 1
34 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
35 Anesthetics, Intravenous Phase 4,Phase 3,Not Applicable
36 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
37 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
38 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Adjuvants, Anesthesia Phase 4,Phase 3,Not Applicable
40 Anesthetics, General Phase 4,Phase 3,Not Applicable
41 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Psychotropic Drugs Phase 4,Phase 3,Phase 2
47 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
48 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
50 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1434)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Unknown status NCT02629510 Phase 4 Tachosil
2 FASTER-Tlalpan Study Unknown status NCT03105856 Phase 4
3 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
4 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Unknown status NCT02910596 Phase 4 bethanechol chloride
5 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
6 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
7 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Unknown status NCT01031069 Phase 4
8 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
9 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
10 CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening (CITRUS Study) Active, not recruiting NCT01895517 Phase 4
11 Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities Terminated NCT00629993 Phase 4
12 To Evaluate the Efficacy and Safety of PEG-rhG-CSF(Jinyouli®) in Reducing Neutropenia in Patients With Cervical Cancer Not yet recruiting NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
13 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
14 Effect of HPV Vaccination on Women Aged 25 Years Completed NCT02296255 Phase 4
15 Comparing Health Services Interventions for the Prevention of HPV-related Cancer Completed NCT02837926 Phase 4
16 Patient Navigation in the Safety Net:CONNECTeDD Completed NCT00613275 Phase 4
17 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
18 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
19 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Recruiting NCT03423082 Phase 4 18F fluciclovine
20 Application of Tachosil During Lymphadenectomy Completed NCT03752606 Phase 4
21 Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls Completed NCT01173900 Phase 4
22 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
23 Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects Completed NCT00947115 Phase 4
24 A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
25 Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India Active, not recruiting NCT00923702 Phase 4
26 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
27 Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy Completed NCT02684942 Phase 4 Meperidine;Fentanyl
28 The KEN SHE Study on HPV-vaccine Efficacy Enrolling by invitation NCT03675256 Phase 4
29 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Recruiting NCT03349463 Phase 4 Fluciclovine F18
30 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
31 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
32 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
33 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
34 Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection Completed NCT01571141 Phase 4
35 Postpartum HPV Vaccination Recruiting NCT03451071 Phase 4 Gardasil9
36 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
37 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
38 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Active, not recruiting NCT03629886 Phase 4
39 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
40 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
41 Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis Unknown status NCT00846508 Phase 3 Cisplatin
42 Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer Unknown status NCT00548821 Phase 3 Cisplatin
43 Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer Unknown status NCT02446652 Phase 3 Hydralazine/Magnesium;Placebo;Carboplatin;Paclitaxel
44 Adjuvant Chemotherapy for Locally Advanced Cervical Cancer Unknown status NCT02036164 Phase 3 Cisplatin;Paclitaxel;Carboplatin
45 Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin
46 Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer Unknown status NCT00842660 Phase 3 Gemzar (gemcitabine)
47 Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
48 Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer Unknown status NCT01999933 Phase 2, Phase 3 cisplatin(DDP) weekly;docetaxel plus cisplatin;docetaxel plus cisplatin
49 Usefulness of FDG-PET for Advanced Cervical Cancer Unknown status NCT00146458 Phase 3
50 Hydralazine Valproate for Cervical Cancer Unknown status NCT00532818 Phase 3 Hydralazine and magnesium valproate;Placebo

Search NIH Clinical Center for Cervical Cancer

Cochrane evidence based reviews: uterine cervical neoplasms

Genetic Tests for Cervical Cancer

Anatomical Context for Cervical Cancer

MalaCards organs/tissues related to Cervical Cancer:

42
Cervix, Testes, Lymph Node, Breast, T Cells, Lung, Uterus

The Foundational Model of Anatomy Ontology organs/tissues related to Cervical Cancer:

20
The Cervix

Publications for Cervical Cancer

Articles related to Cervical Cancer:

(show top 50) (show all 7360)
# Title Authors Year
1
Prevalence of Abnormal Cervical Cancer Screening Outcomes among Screening Compliant Women in the United States. ( 31078510 )
2019
2
Screening Options for Preventing Cervical Cancer. ( 31081850 )
2019
3
HPV-based cervical cancer screening, including self-sampling, versus screening with cytology in Argentina. ( 31097266 )
2019
4
Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer. ( 30926288 )
2019
5
Modeling studies of heterogeneities in glycolytic oscillations in HeLa cervical cancer cells. ( 30927859 )
2019
6
Clinicopathological factors influencing the prognosis of cervical cancer. ( 30941983 )
2019
7
Correction: Automatic classification of cervical cancer from cytological images by using convolutional neural network. ( 30940773 )
2019
8
Change in patterns of failure after image-guided brachytherapy for cervical cancer: analysis from the RetroEMBRACE study. ( 30940530 )
2019
9
SLN mapping in early-stage cervical cancer as a minimal-invasive triaging tool for multimodal treatment. ( 30732972 )
2019
10
Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors. ( 30940131 )
2019
11
MiR-4524b-5p/WTX/β-catenin axis functions as a regulator of metastasis in cervical cancer. ( 30939162 )
2019
12
Regulatory mechanisms of fluvastatin and lovastatin for the p21 induction in human cervical cancer HeLa cells. ( 30939155 )
2019
13
Cervical Cancer Screening Access, Outcomes, and Prevalence of Dysplasia in Correctional Facilities: A Systematic Review. ( 30939063 )
2019
14
Cervical cancer screening decentralized policy adaptation: an African rural-context-specific systematic literature review. ( 30938248 )
2019
15
Deterioration of nutritional status of patients with locally advanced cervical cancer during treatment with concomitant chemoradiotherapy. ( 30938007 )
2019
16
Cervical cancer subtypes harbouring integrated and/or episomal HPV16 portray distinct molecular phenotypes based on transcriptome profiling of mRNAs and miRNAs. ( 30937183 )
2019
17
A 3-step intervention to improve adherence to cervical cancer screening: The SCAN randomized controlled trial. ( 30936001 )
2019
18
TNF-α-induced lncRNA LOC105374902 promotes the malignant behavior of cervical cancer cells by acting as a sponge of miR-1285-3p. ( 30935691 )
2019
19
"Girl, just pray …": Factors That Influence Breast and Cervical Cancer Screening Among Black Women in Rochester, MN. ( 30935680 )
2019
20
Radiation research to determine local tumor invasion in patients with cervical cancer. ( 30932410 )
2019
21
Involvement of NEAT1/miR-133a axis in promoting cervical cancer progression via targeting SOX4. ( 30932200 )
2019
22
The significance of probiotics in preventing radiotherapy-induced diarrhea in patients with cervical cancer: A systematic review and meta-analysis. ( 30928672 )
2019
23
KRT17 confers paclitaxel-induced resistance and migration to cervical cancer cells. ( 30928404 )
2019
24
Combinative evaluation of primary tumor and lymph nodes in predicting pelvic lymphatic metastasis in early-stage cervical cancer: A multiparametric PET-CT study. ( 30927941 )
2019
25
Accuracy of mRNA HPV tests as a predictor of recurrence of precursor lesions and cervical cancer after conization: a systematic review and meta-analysis. ( 30924676 )
2019
26
Melatonin enhances TNF-α-mediated cervical cancer HeLa cells death via suppressing CaMKII/Parkin/mitophagy axis. ( 30923460 )
2019
27
Cervical Cancer Protective Behavioral Patterns Among Mexican Women Living With HPV. ( 30922187 )
2019
28
CytoProcessorTM: A New Cervical Cancer Screening System for Remote Diagnosis. ( 30921788 )
2019
29
Prevalence of cervical cancer and pre-cancerous lesions among unscreened Women in Kumasi, Ghana. ( 30921178 )
2019
30
Using plasma cell free DNA to monitor the chemo-radiotherapy course of cervical cancer. ( 30919951 )
2019
31
MicroRNA-101-5p inhibits the growth and metastasis of cervical cancer cell by inhibiting CXCL6. ( 30915738 )
2019
32
Long noncoding RNA PCAT6 regulates cell growth and metastasis via Wnt/β-catenin pathway and is a prognosis marker in cervical cancer. ( 30915737 )
2019
33
Community-Based Cervical Cancer Education: Changes in Knowledge and Beliefs Among Vietnamese American Women. ( 30915676 )
2019
34
Barriers to the non-acceptance of cervical cancer screenings (pap smear test) in women of childbearing age in a rural area of Peru. ( 30915159 )
2019
35
Deformable image registration for dose mapping between external beam radiotherapy and brachytherapy images of cervical cancer. ( 30913542 )
2019
36
Liquid biopsy of HPV DNA in cervical cancer. ( 30913520 )
2019
37
Synthesis and characterization of gold nanoparticles from aqueous leaf extract of Alternanthera sessilis and its anticancer activity on cervical cancer cells (HeLa). ( 30942109 )
2019
38
Transgelin 2 overexpression inhibits cervical cancer cell invasion and migration. ( 30942422 )
2019
39
Optimal subset of signature miRNAs consisting of 7 miRNAs that can serve as a novel diagnostic and prognostic predictor for the progression of cervical cancer. ( 30942460 )
2019
40
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. ( 30943124 )
2019
41
Effect of miR-301a/PTEN pathway on the proliferation and apoptosis of cervical cancer. ( 30943822 )
2019
42
The Increased PTK7 Expression Is a Malignant Factor in Cervical Cancer. ( 30944666 )
2019
43
Participation in a Swedish cervical cancer screening program among women with psychiatric diagnoses: a population-based cohort study. ( 30885177 )
2019
44
CDK6 3'UTR polymorphisms alter the susceptibility to cervical cancer among Uyghur females. ( 30829464 )
2019
45
Advanced Treatment Technique for Locally Advanced Cervical Cancer: Time for a Standard of Care Shift? ( 30900560 )
2019
46
Testing a Religiously Tailored Intervention with Somali American Muslim Women and Somali American Imams to Increase Participation in Breast and Cervical Cancer Screening. ( 30900079 )
2019
47
Stage and histology of cervical cancer in women under 25 years old. ( 31074235 )
2019
48
Assessment of epigenetic alterations and in silico analysis of mutation affecting PTEN expression among Indian cervical cancer patients. ( 31074114 )
2019
49
Effectiveness of cervical cancer screening at age 65 - A register-based cohort study. ( 30913262 )
2019
50
The Association Between Health Literacy and Breast and Cervical Cancer Screening Behaviors: Findings From the Behavioral Risk Factor Surveillance System. ( 30913171 )
2019

Variations for Cervical Cancer

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

76
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Ser249Cys VAR_004149 rs121913483

ClinVar genetic disease variations for Cervical Cancer:

6 (show top 50) (show all 286)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 FGFR3 NM_000142.4(FGFR3): c.2153A> G (p.Asn718Ser) single nucleotide variant Uncertain significance rs139773438 GRCh38 Chromosome 4, 1806668: 1806668
3 FGFR3 NM_000142.4(FGFR3): c.2153A> G (p.Asn718Ser) single nucleotide variant Uncertain significance rs139773438 GRCh37 Chromosome 4, 1808395: 1808395
4 PIK3CA NM_006218.3(PIK3CA): c.333G> C (p.Lys111Asn) single nucleotide variant Likely pathogenic rs1057519934 GRCh38 Chromosome 3, 179199158: 179199158
5 PIK3CA NM_006218.3(PIK3CA): c.333G> C (p.Lys111Asn) single nucleotide variant Likely pathogenic rs1057519934 GRCh37 Chromosome 3, 178916946: 178916946
6 PIK3CA NM_006218.3(PIK3CA): c.331A> G (p.Lys111Glu) single nucleotide variant Likely pathogenic rs1057519933 GRCh38 Chromosome 3, 179199156: 179199156
7 PIK3CA NM_006218.3(PIK3CA): c.331A> G (p.Lys111Glu) single nucleotide variant Likely pathogenic rs1057519933 GRCh37 Chromosome 3, 178916944: 178916944
8 PIK3CA NM_006218.3(PIK3CA): c.3141T> G (p.His1047Gln) single nucleotide variant Likely pathogenic rs1057519932 GRCh38 Chromosome 3, 179234298: 179234298
9 PIK3CA NM_006218.3(PIK3CA): c.3141T> G (p.His1047Gln) single nucleotide variant Likely pathogenic rs1057519932 GRCh37 Chromosome 3, 178952086: 178952086
10 PIK3CA NM_006218.3(PIK3CA): c.316G> C (p.Gly106Arg) single nucleotide variant Likely pathogenic rs1057519931 GRCh38 Chromosome 3, 179199141: 179199141
11 PIK3CA NM_006218.3(PIK3CA): c.316G> C (p.Gly106Arg) single nucleotide variant Likely pathogenic rs1057519931 GRCh37 Chromosome 3, 178916929: 178916929
12 PIK3CA NM_006218.3(PIK3CA): c.317G> T (p.Gly106Val) single nucleotide variant Uncertain significance rs1057519930 GRCh38 Chromosome 3, 179199142: 179199142
13 PIK3CA NM_006218.3(PIK3CA): c.317G> T (p.Gly106Val) single nucleotide variant Uncertain significance rs1057519930 GRCh37 Chromosome 3, 178916930: 178916930
14 PIK3CA NM_006218.3(PIK3CA): c.241G> A (p.Glu81Lys) single nucleotide variant Likely pathogenic rs1057519929 GRCh38 Chromosome 3, 179199066: 179199066
15 PIK3CA NM_006218.3(PIK3CA): c.241G> A (p.Glu81Lys) single nucleotide variant Likely pathogenic rs1057519929 GRCh37 Chromosome 3, 178916854: 178916854
16 PIK3CA NM_006218.3(PIK3CA): c.2177A> C (p.Glu726Ala) single nucleotide variant Likely pathogenic rs1057519928 GRCh38 Chromosome 3, 179221147: 179221147
17 PIK3CA NM_006218.3(PIK3CA): c.2177A> C (p.Glu726Ala) single nucleotide variant Likely pathogenic rs1057519928 GRCh37 Chromosome 3, 178938935: 178938935
18 PIK3CA NM_006218.2(PIK3CA): c.2176G> A (p.Glu726Lys) single nucleotide variant Pathogenic rs867262025 GRCh38 Chromosome 3, 179221146: 179221146
19 PIK3CA NM_006218.2(PIK3CA): c.2176G> A (p.Glu726Lys) single nucleotide variant Pathogenic rs867262025 GRCh37 Chromosome 3, 178938934: 178938934
20 PIK3CA NM_006218.3(PIK3CA): c.1625A> G (p.Glu542Gly) single nucleotide variant Likely pathogenic rs1057519927 GRCh38 Chromosome 3, 179218295: 179218295
21 PIK3CA NM_006218.3(PIK3CA): c.1625A> G (p.Glu542Gly) single nucleotide variant Likely pathogenic rs1057519927 GRCh37 Chromosome 3, 178936083: 178936083
22 PIK3CA NM_006218.3(PIK3CA): c.1625A> T (p.Glu542Val) single nucleotide variant Likely pathogenic rs1057519927 GRCh38 Chromosome 3, 179218295: 179218295
23 PIK3CA NM_006218.3(PIK3CA): c.1625A> T (p.Glu542Val) single nucleotide variant Likely pathogenic rs1057519927 GRCh37 Chromosome 3, 178936083: 178936083
24 PIK3CA NM_006218.3(PIK3CA): c.1625A> C (p.Glu542Ala) single nucleotide variant Likely pathogenic rs1057519927 GRCh38 Chromosome 3, 179218295: 179218295
25 PIK3CA NM_006218.3(PIK3CA): c.1625A> C (p.Glu542Ala) single nucleotide variant Likely pathogenic rs1057519927 GRCh37 Chromosome 3, 178936083: 178936083
26 NFE2L2 NM_001313902.1(NFE2L2): c.237G> T (p.Glu79Asp) single nucleotide variant Likely pathogenic rs1057519924 GRCh37 Chromosome 2, 178098808: 178098808
27 NFE2L2 NM_001313902.1(NFE2L2): c.237G> T (p.Glu79Asp) single nucleotide variant Likely pathogenic rs1057519924 GRCh38 Chromosome 2, 177234080: 177234080
28 NFE2L2 NM_001145413.3(NFE2L2): c.188A> T (p.Glu63Val) single nucleotide variant Likely pathogenic rs1057519923 GRCh38 Chromosome 2, 177234081: 177234081
29 NFE2L2 NM_001145413.3(NFE2L2): c.188A> T (p.Glu63Val) single nucleotide variant Likely pathogenic rs1057519923 GRCh37 Chromosome 2, 178098809: 178098809
30 NFE2L2 NM_001313904.1(NFE2L2): c.6G> A (p.Lys2=) single nucleotide variant Pathogenic/Likely pathogenic rs1057519922 GRCh38 Chromosome 2, 177234082: 177234082
31 NFE2L2 NM_001313904.1(NFE2L2): c.6G> A (p.Lys2=) single nucleotide variant Pathogenic/Likely pathogenic rs1057519922 GRCh37 Chromosome 2, 178098810: 178098810
32 NFE2L2 NM_001145413.3(NFE2L2): c.187G> C (p.Glu63Gln) single nucleotide variant Likely pathogenic rs1057519922 GRCh38 Chromosome 2, 177234082: 177234082
33 NFE2L2 NM_001145413.3(NFE2L2): c.187G> C (p.Glu63Gln) single nucleotide variant Likely pathogenic rs1057519922 GRCh37 Chromosome 2, 178098810: 178098810
34 NFE2L2 NM_001145412.3(NFE2L2): c.38A> G (p.Asp13Gly) single nucleotide variant Likely pathogenic rs1057519921 GRCh38 Chromosome 2, 177234231: 177234231
35 NFE2L2 NM_001145412.3(NFE2L2): c.38A> G (p.Asp13Gly) single nucleotide variant Likely pathogenic rs1057519921 GRCh37 Chromosome 2, 178098959: 178098959
36 NFE2L2 NM_001313903.1(NFE2L2): c.85G> A (p.Asp29Asn) single nucleotide variant Likely pathogenic rs1057519920 GRCh38 Chromosome 2, 177234232: 177234232
37 NFE2L2 NM_001313903.1(NFE2L2): c.85G> A (p.Asp29Asn) single nucleotide variant Likely pathogenic rs1057519920 GRCh37 Chromosome 2, 178098960: 178098960
38 NFE2L2 NM_001145412.3(NFE2L2): c.37G> T (p.Asp13Tyr) single nucleotide variant Likely pathogenic rs1057519920 GRCh38 Chromosome 2, 177234232: 177234232
39 NFE2L2 NM_001145412.3(NFE2L2): c.37G> T (p.Asp13Tyr) single nucleotide variant Likely pathogenic rs1057519920 GRCh37 Chromosome 2, 178098960: 178098960
40 NFE2L2 NM_001313903.1(NFE2L2): c.85G> C (p.Asp29His) single nucleotide variant Likely pathogenic rs1057519920 GRCh38 Chromosome 2, 177234232: 177234232
41 NFE2L2 NM_001313903.1(NFE2L2): c.85G> C (p.Asp29His) single nucleotide variant Likely pathogenic rs1057519920 GRCh37 Chromosome 2, 178098960: 178098960
42 MTOR NM_004958.3(MTOR): c.6643T> A (p.Ser2215Thr) single nucleotide variant Likely pathogenic rs1057519917 GRCh38 Chromosome 1, 11124517: 11124517
43 MTOR NM_004958.3(MTOR): c.6643T> A (p.Ser2215Thr) single nucleotide variant Likely pathogenic rs1057519917 GRCh37 Chromosome 1, 11184574: 11184574
44 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh38 Chromosome 10, 87933147: 87933147
45 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
46 PIK3CA NM_006218.3(PIK3CA): c.1637A> T (p.Gln546Leu) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh38 Chromosome 3, 179218307: 179218307
47 PIK3CA NM_006218.3(PIK3CA): c.1637A> T (p.Gln546Leu) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
48 PIK3CA NM_006218.3(PIK3CA): c.1637A> C (p.Gln546Pro) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh38 Chromosome 3, 179218307: 179218307
49 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
50 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh37 Chromosome 3, 178936091: 178936091

Copy number variations for Cervical Cancer from CNVD:

7 (show top 50) (show all 142)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 206002 6 13500000 45200000 Loss TAP1 Cervical cancer
2 206001 6 13500000 45200000 Loss NOL7 Cervical cancer
3 206000 1 119851348 119859204 Loss I Cervical cancer
4 205999 6 13500000 45200000 Loss CD83 Cervical cancer
5 32175 1 34400000 39600000 Gain CDCA8 Cervical cancer
6 31746 1 30500000 163800000 Gain AIM2 Cervical cancer
7 30310 1 241700000 247249719 Gain Cervical cancer
8 16425 1 124300000 247249719 Arm Cervical cancer
9 13747 1 1 27800000 Gain EPHB2 Cervical cancer
10 266519 X 98200000 110500000 Gain TMSNB Cervical cancer
11 262572 X 37500000 59500000 Gain SMC1L1 Cervical cancer
12 260239 X 146900000 154913754 Gain CSAG2 Cervical cancer
13 250050 9 19900000 32800000 Loss P16INK4A Cervical cancer
14 246209 9 117700000 141213431 Amplification Cervical cancer
15 246136 9 116700000 140273252 Amplification TRAF2 Cervical cancer
16 246135 9 116700000 140273252 Amplification ST6GALNAC4 Cervical cancer
17 246134 9 116700000 140273252 Amplification SH3GLB2 Cervical cancer
18 246133 9 116700000 140273252 Amplification POMT1 Cervical cancer
19 246132 9 116700000 140273252 Amplification LHX3 Cervical cancer
20 246131 9 116700000 140273252 Amplification CDK9 Cervical cancer
21 244918 9 1 38000000 Loss Cervical cancer
22 235841 8 144899080 144905452 Gain c-Myc Cervical cancer
23 233714 8 12700000 19100000 Loss TUSC3 Cervical cancer
24 232534 8 117700000 146274826 Amplification RECQL4 Cervical cancer
25 232533 8 117700000 146274826 Amplification PTK2 Cervical cancer
26 230720 8 1 12700000 Loss TUSC3 Cervical cancer
27 202456 5 8200000 15100000 Gain TRIO Cervical cancer
28 202450 5 8200000 15100000 Gain ANKH Cervical cancer
29 199081 5 34400000 38500000 Gain SKP2 Cervical cancer
30 199077 5 34400000 38500000 Gain GDNF Cervical cancer
31 194284 5 139000000 143100000 Gain CENTD3 Cervical cancer
32 191717 5 1 48400000 Gain TARS Cervical cancer
33 191716 5 1 48400000 Gain SKP2 Cervical cancer
34 191715 5 1 48400000 Gain SDHA Cervical cancer
35 191714 5 1 48400000 Gain RAD1 Cervical cancer
36 191713 5 1 48400000 Gain POLS Cervical cancer
37 191712 5 1 48400000 Gain PAIP1 Cervical cancer
38 191711 5 1 48400000 Gain OSMR Cervical cancer
39 191710 5 1 48400000 Gain NNT Cervical cancer
40 191709 5 1 48400000 Gain NDUFS6 Cervical cancer
41 191708 5 1 48400000 Gain BRD9 Cervical cancer
42 191707 5 1 48400000 Gain BASP1 Cervical cancer
43 191693 5 1 47700000 Amplification TRIP13 Cervical cancer
44 191692 5 1 47700000 Amplification TRIO Cervical cancer
45 191691 5 1 47700000 Amplification TARS Cervical cancer
46 191690 5 1 47700000 Amplification SUB1 Cervical cancer
47 191689 5 1 47700000 Amplification SLC12A7 Cervical cancer
48 191688 5 1 47700000 Amplification SKP2 Cervical cancer
49 191687 5 1 47700000 Amplification SDHA Cervical cancer
50 191686 5 1 47700000 Amplification RPL37 Cervical cancer

Expression for Cervical Cancer

Search GEO for disease gene expression data for Cervical Cancer.

Pathways for Cervical Cancer

Pathways related to Cervical Cancer according to KEGG:

38
# Name Kegg Source Accession
1 Human papillomavirus infection hsa05165
2 Viral carcinogenesis hsa05203

Pathways related to Cervical Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 164)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.31 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
2
Show member pathways
14.16 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 HRAS
3
Show member pathways
14.01 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
4
Show member pathways
13.84 AKT1 CCND1 ERBB2 FGFR3 GNAS HRAS
5
Show member pathways
13.84 AKT1 CTNNB1 ERBB2 FGFR3 HRAS MTOR
6
Show member pathways
13.8 AKT1 ERBB2 FGFR3 GNAS HRAS MTOR
7
Show member pathways
13.69 AKT1 ERBB2 FGFR3 GNAS HRAS MTOR
8
Show member pathways
13.67 AKT1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
9
Show member pathways
13.62 AKT1 CTNNB1 ERBB2 FGFR3 HRAS PIK3CA
10
Show member pathways
13.58 AKT1 ERBB2 FGFR3 HRAS MTOR PIK3CA
11
Show member pathways
13.57 AKT1 CCND1 ERBB2 FGFR3 GNAS HRAS
12
Show member pathways
13.5 AKT1 CCND1 ERBB2 FGFR3 HRAS PIK3CA
13
Show member pathways
13.42 AKT1 CTNNB1 ERBB2 FGFR3 HRAS PTEN
14
Show member pathways
13.38 AKT1 CCND1 ERBB2 GNAS HRAS MTOR
15
Show member pathways
13.21 AKT1 FGFR3 GNAS HRAS MTOR PTEN
16
Show member pathways
13.17 AKT1 FGFR3 GNAS HRAS MTOR STAT3
17
Show member pathways
13.13 AKT1 CTNNB1 GNAS HRAS STAT3 TP53
18
Show member pathways
13.11 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
19
Show member pathways
13.1 AKT1 CTNNB1 HRAS MTOR PIK3CA PTEN
20
Show member pathways
13.09 AKT1 CCND1 CTNNB1 GNAS HRAS MTOR
21
Show member pathways
13.07 AKT1 ERBB2 HRAS MTOR PIK3CA PTEN
22
Show member pathways
13.07 AKT1 CCND1 CTNNB1 ERBB2 HRAS PIK3CA
23
Show member pathways
13.06 AKT1 ERBB2 FGFR3 GNAS HRAS MTOR
24
Show member pathways
13.02 AKT1 CCND1 GNAS HRAS PIK3CA STAT3
25
Show member pathways
12.98 AKT1 CCND1 CTNNB1 ERBB2 HRAS MTOR
26
Show member pathways
12.96 AKT1 CCND1 HRAS MTOR PIK3CA PTEN
27
Show member pathways
12.93 AKT1 ERBB2 FGFR3 HRAS MTOR PIK3CA
28
Show member pathways
12.92 AKT1 CTNNB1 GNAS HRAS MTOR
29
Show member pathways
12.91 AKT1 CTNNB1 ERBB2 HRAS MTOR PIK3CA
30
Show member pathways
12.89 AKT1 CTNNB1 FGFR3 GNAS HRAS PIK3CA
31 12.88 AKT1 ERBB2 FGFR3 HRAS TP53
32
Show member pathways
12.87 AKT1 CCND1 CTNNB1 GNAS HRAS MTOR
33
Show member pathways
12.84 AKT1 CCND1 CTNNB1 ERBB2 HRAS MTOR
34
Show member pathways
12.8 AKT1 CCND1 ERBB2 HRAS MTOR PIK3CA
35
Show member pathways
12.79 AKT1 CCND1 ERBB2 FGFR3 GNAS HRAS
36
Show member pathways
12.77 AKT1 CTNNB1 ERBB2 HRAS PIK3CA STAT3
37
Show member pathways
12.73 AKT1 CCND1 CTNNB1 MTOR STAT3
38
Show member pathways
12.72 AKT1 ERBB2 FGFR3 HRAS MTOR PIK3CA
39
Show member pathways
12.71 AKT1 GNAS HRAS PIK3CA STAT3
40
Show member pathways
12.7 AKT1 CCND1 ERBB2 HRAS MTOR PIK3CA
41
Show member pathways
12.67 AKT1 HRAS MTOR PIK3CA PTEN
42
Show member pathways
12.66 AKT1 CCND1 CTNNB1 ERBB2 HRAS MTOR
43
Show member pathways
12.63 AKT1 HRAS MTOR PIK3CA STAT3
44
Show member pathways
12.63 AKT1 CTNNB1 ERBB2 FGFR3 HRAS MTOR
45
Show member pathways
12.62 AKT1 CCND1 HRAS MTOR PIK3CA TP53
46
Show member pathways
12.59 AKT1 CCND1 HRAS MTOR PIK3CA STAT3
47 12.58 AKT1 CCND1 CTNNB1 GNAS TP53
48
Show member pathways
12.57 CTNNB1 ERBB2 FGFR3 HRAS MTOR PIK3CA
49 12.57 AKT1 CCND1 CTNNB1 HRAS PIK3CA SMAD4
50
Show member pathways
12.57 AKT1 CCND1 HRAS MTOR PIK3CA PTEN

GO Terms for Cervical Cancer

Cellular components related to Cervical Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 AKT1 CCND1 CTNNB1 ERBB2 GNAS MTOR
2 cytoplasm GO:0005737 9.5 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
3 nucleus GO:0005634 10 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.97 AKT1 CTNNB1 HRAS MIR21 MIR214
2 positive regulation of cell proliferation GO:0008284 9.97 AKT1 CCND1 CTNNB1 FGFR3 HRAS MIR21
3 aging GO:0007568 9.96 AKT1 NFE2L2 PTEN STAT3
4 protein autophosphorylation GO:0046777 9.96 AKT1 ERBB2 FGFR3 MTOR
5 positive regulation of MAPK cascade GO:0043410 9.92 CTNNB1 ERBB2 FGFR3 HRAS
6 positive regulation of protein kinase B signaling GO:0051897 9.89 ERBB2 FGFR3 MIR21 MTOR PIK3CA
7 response to estradiol GO:0032355 9.88 CCND1 CTNNB1 PTEN STAT3
8 negative regulation of apoptotic process GO:0043066 9.88 AKT1 CTNNB1 MIR21 PTEN STAT3 TP53
9 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.87 MIR21 PTEN SMAD4
10 negative regulation of cell death GO:0060548 9.86 NFE2L2 SMAD4 STAT3
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.86 FGFR3 HRAS MIR21 PTEN
12 negative regulation of cell proliferation GO:0008285 9.86 CTNNB1 HRAS MIR21 MIR214 PTEN SMAD4
13 positive regulation of osteoblast differentiation GO:0045669 9.85 CTNNB1 GNAS MIR21
14 cellular response to growth factor stimulus GO:0071363 9.85 AKT1 CTNNB1 ERBB2
15 response to organic substance GO:0010033 9.85 AKT1 CCND1 PTEN STAT3
16 negative regulation of neuron death GO:1901215 9.84 AKT1 CTNNB1 STAT3
17 protein kinase B signaling GO:0043491 9.8 AKT1 PIK3CA PTEN
18 positive regulation of protein phosphorylation GO:0001934 9.8 AKT1 CCND1 ERBB2 HRAS MIR21 MTOR
19 activation of protein kinase B activity GO:0032148 9.78 AKT1 MIR21 MTOR
20 phosphatidylinositol 3-kinase signaling GO:0014065 9.77 AKT1 ERBB2 PIK3CA
21 cell aging GO:0007569 9.76 HRAS MTOR TP53
22 positive regulation of epithelial to mesenchymal transition GO:0010718 9.73 CTNNB1 MIR21 MTOR SMAD4
23 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.71 MIR21 MIR214 NFE2L2
24 regulation of mitochondrial membrane permeability GO:0046902 9.7 STAT3 TP53
25 regulation of protein kinase B signaling GO:0051896 9.7 MIR21 MTOR
26 response to leptin GO:0044321 9.7 CCND1 STAT3
27 cellular response to leptin stimulus GO:0044320 9.7 PTEN STAT3
28 regulation of myelination GO:0031641 9.7 AKT1 CTNNB1 MTOR
29 positive regulation of metalloendopeptidase activity GO:1904685 9.69 MIR21 STAT3
30 negative regulation of macroautophagy GO:0016242 9.69 AKT1 MTOR PIK3CA
31 mitotic G1 DNA damage checkpoint GO:0031571 9.68 CCND1 TP53
32 endothelial tube morphogenesis GO:0061154 9.68 CTNNB1 MIR21
33 regulation of glycogen biosynthetic process GO:0005979 9.67 AKT1 MTOR
34 hair follicle placode formation GO:0060789 9.65 CTNNB1 GNAS
35 anoikis GO:0043276 9.65 AKT1 MTOR PIK3CA
36 cellular response to decreased oxygen levels GO:0036294 9.63 AKT1 PTEN
37 negative regulation of cell size GO:0045792 9.63 AKT1 MTOR PTEN
38 cellular response to hypoxia GO:0071456 9.63 AKT1 MIR214 MTOR NFE2L2 PTEN TP53
39 response to UV-A GO:0070141 9.61 AKT1 CCND1
40 cell proliferation GO:0008283 9.56 AKT1 CTNNB1 ERBB2 HRAS PTEN SMAD4
41 positive regulation of transcription by RNA polymerase III GO:0045945 9.4 MTOR
42 positive regulation of gene expression GO:0010628 9.32 AKT1 CTNNB1 ERBB2 MTOR MIR21 HRAS
43 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 AKT1 CTNNB1 HRAS NFE2L2 SMAD4 STAT3
44 phosphorylation GO:0016310 10.14 AKT1 ERBB2 FGFR3 MTOR PIK3CA STAT3
45 protein phosphorylation GO:0006468 10.13 AKT1 CCND1 ERBB2 FGFR3 MTOR PIK3CA
46 nervous system development GO:0007399 10.11 AKT1 CTNNB1 ERBB2 PTEN STAT3
47 positive regulation of transcription, DNA-templated GO:0045893 10.11 AKT1 CTNNB1 NFE2L2 SMAD4 STAT3 TP53
48 positive regulation of apoptotic process GO:0043065 10.04 AKT1 CTNNB1 MIR21 PTEN TP53
49 response to drug GO:0042493 10.03 CCND1 CTNNB1 GNAS PTEN STAT3
50 cytokine-mediated signaling pathway GO:0019221 10 AKT1 CCND1 PIK3CA STAT3 TP53

Molecular functions related to Cervical Cancer according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.88 AKT1 CCND1 ERBB2 FGFR3 MTOR PIK3CA
2 transcription regulatory region DNA binding GO:0044212 9.78 NFE2L2 SMAD4 STAT3 TP53
3 identical protein binding GO:0042802 9.76 AKT1 ERBB2 FGFR3 MTOR PTEN SMAD4
4 nucleotide binding GO:0000166 9.73 ERBB2 FGFR3 HRAS MTOR
5 enzyme binding GO:0019899 9.72 AKT1 CCND1 CTNNB1 PTEN TP53
6 transcription factor binding GO:0008134 9.65 CCND1 CTNNB1 NFE2L2 STAT3 TP53
7 RNA polymerase II transcription factor binding GO:0001085 9.54 CTNNB1 SMAD4 TP53
8 I-SMAD binding GO:0070411 9.49 CTNNB1 SMAD4
9 protein phosphatase binding GO:0019903 9.26 CTNNB1 ERBB2 STAT3 TP53
10 protein kinase binding GO:0019901 9.17 AKT1 CCND1 CTNNB1 MTOR PTEN STAT3
11 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.16 PIK3CA

Sources for Cervical Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....